Align Technology (NASDAQ:ALGN) been upgraded to outperform from market perform by Leerink Partners. Calling Align ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Faisal Khurshid, an analyst from Leerink Partners, maintained the Buy rating on Geron (GERN – Research Report). The associated price target ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Leerink upgraded Quest Diagnostics (DGX) to Outperform from Market Perform with a price target of $174, up from $169. The firm notes its view ...

Stock analysts at Leerink Partnrs boosted their Q2 2025 earnings per share (EPS) estimates for shares of Cencora in a research report issued on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Align Technology upgraded by Leerink Partners with a $280 price target, citing growth potential, stock buyback plans, and global market expansion.

Quest Diagnostics (NYSE:DGX – Get Free Report) was upgraded by Leerink Partners from a “market perform” rating to an ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...

Beta Bionics, a medical equipment manufacturer, has filed for an initial public offering with the Securities and Exchange Commission. It plans to list shares on Nasdaq under the ticker BBNX. The ...